Perrigo Announces FDA Final Approval For Generic Version Of Androgel

Nelson Vergel

Founder, ExcelMale.com
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing AbbVie Inc.'s Androgel® Topical Gel, 1.62% packets (20.25 mg/1.25 g packet and 40.5 mg/2.5 g packet).

Androgel® Topical Gel, 1.62% packets is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Annual market sales for Androgel® Topical Gel, 1.62% packets for the 12 months ending May 2017 were approximately $88 million.

Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, "This final approval is another example of our long-term investment in new products. The Rx team remains committed to providing affordable treatments options for patients in important extended topical categories."

Source
 

hCG Mixing Calculator

HCG Mixing Protocol Calculator

Online statistics

Members online
5
Guests online
688
Total visitors
693

Latest posts

Back
Top